U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H20N4O8S2
Molecular Weight 532.5492
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CEFSULODIN

SMILES

c1ccc(cc1)[C@]([H])(C(=N[C@]2([H])C(=O)N3C(=C(C[n+]4ccc(cc4)C(=N)O)CS[C@]23[H])C(=O)O)O)S(=O)(=O)[O-]

InChI

InChIKey=SYLKGLMBLAAGSC-QLVMHMETSA-N
InChI=1S/C22H20N4O8S2/c23-18(27)13-6-8-25(9-7-13)10-14-11-35-21-15(20(29)26(21)16(14)22(30)31)24-19(28)17(36(32,33)34)12-4-2-1-3-5-12/h1-9,15,17,21H,10-11H2,(H4-,23,24,27,28,30,31,32,33,34)/t15-,17-,21-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/3536385 | http://www.229877.com/article/2013/0126/32350.html

Cefsulodin is a third-generation of cephalosporin antibiotic with a narrow spectrum of activity. It has a specific activity against Pseudomonas aeruginosa. Cefsulodin’s targets are bacterial penicillin binding proteins. Drug is indicated for the treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms. Cefsulodin appears to be well tolerated and relatively free of any significant toxicity except for nausea and vomiting.

CNS Activity

CNS Penetrant
2344
Curator's Comment:: Known to be CNS penetrant in rat. Human data not available

Originator

Takeda Chemical Industries
26
Curator's Comment:: # Takeda Chemical Industries, Ltd.

Approval Year

Unknown
109281
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
7728
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8043
Takesulin

Approved Use

Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Curative
Approved
8043
Takesulin

Approved Use

Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Curative
Approved
8043
Takesulin

Approved Use

Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Curative
Approved
8043
Takesulin

Approved Use

Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Curative
Approved
8043
Takesulin

Approved Use

Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Curative
Approved
8043
Takesulin

Approved Use

Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Curative
Approved
8043
Takesulin

Approved Use

Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
Curative
Approved
8043
Takesulin

Approved Use

Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms.
PubMed

PubMed

TitleDatePubMed
IgE antibodies for penicillins and cephalosporins in rats. III. Antigenic specificity of rat anti-cephalosporin-OvA IgE sera.
1981 Jan
Epitope analysis of aztreonam by antiaztreonam monoclonal antibodies and possible consequences in beta-lactams hypersensitivity.
1992
Patents

Patents

JP2001500477A
110
JP4763957B2
79
JPS606617A
6

Sample Use Guides

In Vivo Use Guide
Intramuscular: 0.5-1 g daily in 2-4 divided doses Intravenous: 0.5-1 g. in severe cases up to 2 g.
Route of Administration: Other
In Vitro Use Guide
Cefsulodin was an effective bactericidal agent against P. aeruguiosa and S. aureus. An apparent decrease in the number of living bacteria was observed at a concentration of 6.25 ug/ml for P. aerugnosa U 31 and 3.13 ug/ml for S. aureus FDA 209- P.
Name Type Language
CEFSULODIN
INN   MI   WHO-DD  
INN  
Official Name English
CEFSULODIN [MI]
Common Name English
CEFSULODIN [INN]
Common Name English
4-CARBAMOYL-1-(((6R,7R)-2-CARBOXY-8-OXO-7-((2R)-2-PHENYL-2-SULFOACETAMIDO)-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-EN-3-YL)METHYLPYRIDINIUM HYDROXIDE, INNER SALT
Common Name English
CEFSULODIN [WHO-DD]
Common Name English
CEFSULODIN [JAN]
Common Name English
J01DD03
Code English
Classification Tree Code System Code
WHO-ATC J01DD03
Created by admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
NCI_THESAURUS C357
Created by admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
WHO-VATC QJ01DD03
Created by admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
Code System Code Type Description
EVMPD
SUB07420MIG
Created by admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
PRIMARY
ChEMBL
CHEMBL1617285
Created by admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
PRIMARY
CAS
62587-73-9
Created by admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
PRIMARY
INN
4390
Created by admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
PRIMARY
RXCUI
2190
Created by admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
PRIMARY RxNorm
MERCK INDEX
M3216
Created by admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
PRIMARY Merck Index
DRUG BANK
DB13499
Created by admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
PRIMARY
MESH
D002441
Created by admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
PRIMARY
PUBCHEM
656575
Created by admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
PRIMARY
FDA UNII
OV42LHE42B
Created by admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
PRIMARY
NCI_THESAURUS
C98227
Created by admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
PRIMARY
DRUG CENTRAL
558
Created by admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
PRIMARY
WIKIPEDIA
CEFSULODIN
Created by admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
PRIMARY
EPA CompTox
62587-73-9
Created by admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
PRIMARY
ACTIVE MOIETY
Structure of CEFSULODIN
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966